N,2-dicyclohexyl-2-(2-(4-(methylsulfonyl)phenyl)-1H-benzo[d]imidazol-1-yl)acetamide | 1266357-65-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N,2-dicyclohexyl-2-(2-(4-(methylsulfonyl)phenyl)-1H-benzo[d]imidazol-1-yl)acetamide
• 英文别名: N,2-dicyclohexyl-2-[2-(4-methylsulfonylphenyl)benzimidazol-1-yl]acetamide
• CAS: 1266357-65-6
• 化学式: C₂₈H₃₅N₃O₃S
• 分子量: 493.67
• InChiKey: CHZLKWIUSQUGKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  89.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  tert-butyl (2-(N-(1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl)-4-(methylsulfonyl)benzamido)phenyl)carbamate 在 三氟乙酸 作用下， 生成 N,2-dicyclohexyl-2-(2-(4-(methylsulfonyl)phenyl)-1H-benzo[d]imidazol-1-yl)acetamide
  参考文献：
  名称：

  Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes

  摘要：

  Herein we describe the synthesis and structure activity relationship of a new class of FXR agonists identified from a high-throughput screening campaign. Further optimization of the original hits led to molecules that were highly active in an LDL-receptor KO model for dyslipidemia. The most promising candidate is discussed in more detail. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.039

文献信息

• Novel benzimidazole derivatives
  申请人：Benson Martin Gregory

  公开号：US20080021027A1

  公开（公告）日：2008-01-24

  The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R 1 to R 8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.

  这项发明涉及公式（I）的新型苯并咪唑衍生物，其中R1至R8如描述和权利要求中所定义，以及其生理上可接受的盐和酯。这些化合物与法尼索酮-X-受体（FXR）结合，并可用于治疗由FXR激动剂调节的疾病，例如糖尿病和血脂异常。
• A FARNESOID X RECEPTOR AGONSITS FORUSE AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3711762A1

  公开（公告）日：2020-09-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

  本发明涉及治疗乙型肝炎病毒感染的方法和药物组合物。特别是，本发明涉及法尼类固醇 X 受体（FXR）激动剂，用于治疗有需要的受试者的乙型肝炎病毒感染的方法。
• Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE)

  公开号：US10071108B2

  公开（公告）日：2018-09-11

  The present invention relates to methods and pharmaceutical compositions for the treatment of hepatitis B virus infection. In particular, the present invention relates to farnesoid X receptor (FXR) agonists for use in a method for the treatment of hepatitis B virus infection in a subject in need thereof.

  本发明涉及治疗乙型肝炎病毒感染的方法和药物组合物。特别是，本发明涉及法尼类固醇 X 受体（FXR）激动剂，用于治疗有需要的受试者的乙型肝炎病毒感染的方法。
• BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP2038259A1

  公开（公告）日：2009-03-25
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
  申请人：Institut National de la Santé et de la Recherche Médicale (INSERM)

  公开号：EP3043865A1

  公开（公告）日：2016-07-20